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Abstract
Background: Cardiovascular (CV) complications are the most significant cause of mortality in 
adults with Cushing disease (CD); little is known about CV risk factors in children with CD. 
Measurement of lipoprotein particles by nuclear magnetic resonance (NMR) spectroscopy is a 
novel technology to assess CV risk. The objective of the current study is to analyze the NMR lipid 
profile in pediatric CD patients before and 1 year after remission.
Methods: NMR lipid profile was obtained via the Vantera NMR analyzer, using frozen serum 
samples from 33 CD patients (mean age 13.8 ± 4.0 years) evaluated between 1997 and 2017 at the 
National Institutes of Health (NIH) Clinical Center (CC).
Results: GlycA, triglyceride-rich particles (TRLP medium and very small sizes), LDL particles 
(LDLP total and large size), HDL particles (HDLP total, medium and small sizes), total 
cholesterol, LDL cholesterol, HDL cholesterol, GlycA inflammatory biomarker, Apolipoprotein B 
and Apolipoprotein A1 concentrations showed statistically significant changes after remission of 
CD (p<0.05).
Conclusion: In our study population, most of the lipid variables improved post-CDremission, 
with the exception of HDL and apoA1, indicating that NMR lipoprotein profile may be a helpful 
tool in assessing the cardiovascular risk in pediatric patients with CD.
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Introduction
Cushing disease (CD) is a rare disease in pediatrics, with an estimated incidence of 1 to 1.5 
per million children per year [1]. It is caused by ACTH overproduction from the pituitary, 
most often due to an ACTH-secreting pituitary microadenoma. The prolonged 
hypercortisolism results in the typical Cushing syndrome (CS) signs and symptoms: truncal 
obesity, growth deceleration, skin changes, muscle weakness, and hypertension [2, 3].
Cardiovascular complications are the most significant cause of mortality in adult patients 
with CD, with an estimated cardiovascular mortality rate 4-5 times higher than the general 
population [4, 5]. A recent meta-analysis of 14 studies reports higher prevalence of markers 
of early atherosclerosis in 332 adult patients with CS compared to 462 controls [6]. 
Cardiovascular risk factors, including metabolic syndrome, atherosclerotic plaques, elevated 
low-density lipoprotein, and total cholesterol levels, may persist in adults even after surgical 
remission has been achieved [7].
Pediatric studies of cardiovascular involvement in CD are limited. Our group had previously 
showed that pediatric CD patients exhibit a significant improvement of hypertension after 
remission is achieved, however, they remain at risk for residual hypertension[8]. We also 
showed that pediatric CD patients are at increased risk for metabolic syndrome with more 
than 60% of our cohort exhibiting signs of insulin resistance based on HOMA-IR values [9].
Measurement of lipoprotein particles using nuclear magnetic resonance (NMR) 
spectroscopy is a novel technology to assess cardiovascular risk. NMR spectroscopy 
measures the signals generated by the terminal methyl groups on lipids; lipoprotein subclass 
concentrations are then derived from deconvolution of the lipid methyl signal. The Vantera 
Clinical Analyzer is the first NMR device cleared by the FDA for use as a clinical 
instrument; it measures particle concentrations for all lipoprotein classes (VLDL, LDL, 
HDL) and subclasses (large, medium, small), as well as particle sizes for VLDL, LDL and 
HDL [10].
The lipoprotein particles transport cholesterol and triglycerides in the bloodstream and are 
direct mediators of atherosclerosis; LDL particles initiate formation of cholesterol-rich foam 
cells and atherosclerotic plaque, while HDL particles potentially mediate the reverse 
cholesterol transport by inhibiting the oxidation of LDL particles and removing cholesterol 
from the foam cells for delivery back to the liver [11-13]. The small LDL particles are 
considered more atherogenic than the large LDL particles with previous studies showing that 
lower levels of LDL and HDL mean particle sizes are associated with insulin resistance [14, 
15].Two recent large scale studies in obese, pre-diabetic, and type 2 diabetic adolescents and 
young adults showed that NMR lipid profile is a better indicator of vascular damage 
compared to the traditional lipid profile [16, 17].
The goal of the current study was to assess the lipoprotein profile in pediatric patients with 
CD before treatment and 1 year after biochemical remission was achieved. We hypothesized 
that remission of CD would improve the NMR lipid variables. Furthermore, we investigated 
potential correlations between lipoprotein variables and clinical markers of CD severity, 
using the CD severity score and its individual components, as described previously [1].
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Patients, Materials and Methods
Patient population
Out of 211 pediatric CD patients (<21 years old) evaluated under the research protocol 97-
CH-0076 of the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (NICHD) (January 1997 until August 2017), we identified 33 patients who 
remained in remission at 1 year after transsphenoidal surgery (TSS) and for whom frozen 
serum or plasma samples were available. The study was approved by the Investigational 
Review Board of NICHD and all patients and/or their parents gave written assent/consent. 
The NIH Clinical Research Information System was used to obtain medical records and 
clinical data. Samples were obtained at their initial evaluation and at the one-year post 
transsphenoidal resection (TSS) follow-up visit. For the purposes of this study, we defined 
remission of CD only based on biochemical criteria as follows: midnight cortisol <4.4mcg/dl 
and/or urinary free cortisol levels within the normal range at 12 months post-TSS.
NMR spectroscopy
NMR spectroscopy profile was obtained via the Vantera analyzer (LipoScience/LabCorp 
Global Research Services) at the Department of Laboratory Medicine at the NIH Clinical 
Center, using the LP4 algorithm. All the measurements were performed on the same 
analyzer. Between-day coefficient of variation is less than 11%, as determined in the 
performing lab. The following six categories of lipid variables were obtained (table 1): 1) 
Triglyceride-rich particles (TRLP-total, very large, large, medium, small and very small) are 
reported as nanomoles per liter with mean reference range valuesat 125.2±61.6, 0.4±1.0, 
2.9±6.5, 17.9±16.2, 56.5±37.5 and 47.5±46.9 nmol/L respectively, 2) Low-density 
lipoprotein particle concentrations (LDLP-total, large, medium and small) are reported as 
nanomoles per liter with mean reference range values at 1454.0±393, 309.0±223, 676.0±405 
and 469.0±431 nmol/L respectively, 3) High-density lipoprotein particle concentrations 
(HDLP-total, large, medium and small) are reported as micromoles per liter with mean 
reference range values at 24.0±3.0, 2.5±1.9, 7.7±2.7, 13.8±3.4 μmol/L respectively, 4) Mean 
particle sizes (triglyceride rich-TRLZ, low density lipoprotein-LDLZ and high density 
lipoprotein-HDLZ) are reported as nanometers with mean reference range values at 
44.0±8.4, 21.0±0.5 and 8.98±0.44 nm respectively, 5) Lipids and apolipoproteins (total 
triglycerides-TG, total cholesterol-TC, TRL triglycerides-TRLTG, LDL cholesterol-LDLC, 
HDL cholesterol-HDLC, apolipoprotein B-apoB and apolipoprotein A1-apoA1) are reported 
as milligrams per deciliter with mean reference range values at 119.3±89.8, 193.8±36.5, 
99.1±88.7, 110.5±30.7, 61.1±14.4, 87.1±23.6 and 156.8±27.8 mg/dl respectively, and finally 
6) inflammatory biomarker GlycA (glycosylated acute phase proteins) is reported as 
micromoles per liter with mean reference range value at 402.4±65.8μmol/L.
Cushing disease severity score
The CD severity score was previously introduced by our group to quantify the clinically 
relevant manifestations of cortisol exposure in children. Seven individual factors are used in 
the scoring (degree of hypercortisolemia, impaired glucose tolerance, hypertension, height z-
score, BMI z-score, time to diagnosis, and tumor size) and each of these factors has been 
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independently associated with worse outcome. A full description of the CD severity score is 
outlined in the paper by Gkourogianni et al [1].
Statistical analysis
All summary statistics are reported as mean ± SD. All reported p-values are two-tailed, with 
p<0.05 considered to be statistically significant. Paired comparisons utilizing either the 
paired t-test or non-parametric Wilcoxon signed-rank test were performed to compare 
lipoprotein variables in cured CD patients before and 1-year after TSS. In these paired 
comparisons, stepdown Bonferroni corrections for multiple comparisons were carried outfor 
groups of related measures,and corrected p-values are reported where applicable.Correlation 
analyses were done using Pearson’s correlation coefficient or Spearman’s rho, as 
appropriate, between CD severity score parameters and the patients’ lipoprotein profile. Data 
were analyzed using SAS v9.4 (SAS Institute, Inc, Cary, NC).
Results
Patient population
Out of 211 pediatric CD patients (<21 years old) evaluated at NIH since 1997, we identified 
33 patients (11 males, 22 females, mean age 13.8 ± 4.0years) who achieved biochemical 
remission at 1 year post-TSS and for whom pre- and post-surgery frozen serum or plasma 
samples were available. Pre- and post-surgery samples were drawn between 0-12 months 
before TSS, and 3-13 months (except two at 48 and 49 months) after TSS. Clinical and 
biochemical characteristics of CD patients are summarized in table 2.
NMR spectroscopy
Six categories of NMR lipid variables were analyzed in 33 CD patients in remission and 
their values were compared before and after surgery. As pediatric normative data for the 
NMR lipid parameters are not available in the literature thus far, we compared the delta 
changes of each lipid variable before and after cure (table 3). There were robust, statistically 
significant effects on several lipid variables: GlycA (delta=−69.0, 95% CI −115.6 – −22.4), 
triglyceride rich particles TRLP (medium: delta = 6.2, 95% CI 1.9-10.5; and very small: 
delta = −27.1, 95% CI −44.1- −10.2), LDLP (total: delta = −271.6, 95% CI −465.4 – −77.7; 
and large: delta = −142.9, 95% CI −235.1 – −50.6), HDLP (total: delta = −3.6, 95% CI −5.6 
– −1.6; medium: delta = −2.0,95% CI −3.2 – −0.7; and small: delta = −1.9,95% CI −3.1 – 
−0.8), TC (delta = −31.5, 95% CI −53.7 – −9.3), LDLC (delta = −23.1,95% CI −39.3 – 
−6.8), HDLC (delta = −7.5, 95% CI −13.2 – −1.9), ApoB(delta = − 16.5,95% CI −28.3 – 
−4.8) and ApoA1 (delta = −17.5, 95% CI −31.2 – −3.9).
CD severity score
CD severity score was calculated as following: degree of hypercortisolemia (24 hour UFC 
normal = 0; 24 hour UFC up to 3x normal = 1; 24 hour UFC > 3x normal = 2), impaired 
glucose tolerance (fasting plasma glucose FPG <100 = 0; FGP >= 100 = 1; FPG >=126 or 
diabetes mellitus diagnosis = 2), hypertension (SBP & DBP z-score both <2=0; SBP or DBP 
z score >= 2 =1; HTN-Tx = 2), height z-score (>−0.5 = 0; <=−0.5 = 1), BMI z-score (<2 = 
0; >=2 = 1), time to diagnosis (<3 years = 0; >=3 = 1) and tumor characteristics (adenoma 
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<5 mm = 0; adenoma >=5 mm and or CS invasion = 1). Pre-TSS GlycA, TRLP (medium 
and very small sizes), LDLP (large size), HDLP (medium size), HDLC, ApoA1 showed 
statistically significant individual correlations with one or more of the following CD severity 
score variables: BMI z-score, 24-h urinary cortisol concentrations, midnight serum cortisol 
levels, early morning serum cortisol levels, and age at surgery.
Table 4 summarizes the correlations of individual NMR lipid variables with CD severity 
score variables that reached statistical significance and carry potential importance. Total 
HDL-particle, apolipoprotein A1 (surrogate of HDL) and HDL cholesterol are all considered 
to exert a protective cardiovascular effect and all showed a reverse correlation with pre-TSS 
morning serum cortisol levels (r=−0.36, r= −0.45 and r=−0.50, respectively), indicating that 
the higher the degree of hypercortisolemia, the worse the patient’s HDL lipid profile (Figure 
1a,1b, and 1d). Also, the very small triglyceride rich particles (VSTRLP), that act by 
inhibiting the protective mechanism of lipolysis, showed a positive correlation with the 
morning cortisol values (r=0.37) and also exhibited a robust post-TSS decrease by −27.1 
(p=0.0162) (table 3). Thus, a higher cortisol level, which indicates more severe CD, is 
clinically correlated with a higher VSTRLP value (Figure 1c). Finally, GlycA, a novel 
inflammatory biomarker, that showed a robust postop decrease by −69.0 (p=0.0050), also 
exhibited a positive correlation with BMI z-score (r=0.47). The higher the BMI, the worse 
the CD, which clinically correlates with a higher GlycA level (Figure 2).
Discussion
This is the first study to our knowledge to report NMR spectroscopy data in pediatric 
patients with CD in order to assess their cardiovascular risk. We hypothesized that 
normalization of cortisol levels post-TSS would improve the patient’s lipoprotein levels and 
thus have a positive effect on their atherogenic profile. In contrast to regular lipid profile that 
only measures lipoprotein concentrations, NMR has the ability to measure lipoprotein 
particle number, size, and concentration [12].
Clinical interpretation of the individual NMR lipid variables is not yet well-established in 
the literature. The total LDL-particle (LDLP) is approved by the FDA for clinical use in 
adults. Matyus et al examined the analytical performance of the NMR-based LDLP assay as 
per clinical laboratory standards institute (CLSI) guidelines and report mean LDLP value at 
1193 ± 472 nmol/L (95% CI 457-2282) [10]. In our pediatric population, the mean pre-TSS 
value was 1,751.1± 578.5 and decreased to 1479.5 ± 506.2 post-surgery (p=0.0225), which 
represents a significant post-cure decrease; however it did not reach the normal adult 
reference range of <1,200nmol/L. 21% of our patients continued to have abnormal LDLP 
levels at 1 year follow up, implying that some lipid abnormalities may persist even after CD 
is cured. A recent study reported total LDLP values, as part of the NMR lipid profile, using 
the 400-MHz proton NMR analyzer at Liposcience, in 232 lean, 228 obese and 214 type 2 
diabetics adolescents and young adults at 849.7 ± 248, 1102.6 ± 326.8 and 1257 
± 437.9nmol/L respectively [16]. Shah et al measured NMR lipoprotein data, using the 
LipoProfile-3 algorithm by LipoScience, in 118 obese normoglycemic and 96 obese 
prediabetic youth; mean total LDLP levels were1037 (834, 1266) and 1098 (898, 1353) 
nmol/L respectively [17]. As compared to both these studies, keeping in mind that 
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coefficient variations between machines may be a consideration, our patient population had 
much higher LDLP values even after CD was cured, implying that the dyslipidemia 
associated with CD might be more severe than the degree of dyslipidemia associated with 
obesity or type 2 diabetes mellitus.
All LDL particles decreased post-cure, however, only the total and large LDL particles were 
statistically significant. Furthermore, very small TRLP, a very proatherogenic form of 
triglyceride-rich particles, showed a significant post-TSS decrease by −27.1 (p=0.0162). The 
GlycA NMR signal is a novel inflammatory biomarker that reflects the aggregated levels of 
several glycosylated acute phase proteins and is associated with increased cardiovascular 
disease risk in adults [18]. In our study, GlycA levels decreased post-cure, indicating an 
improvement in the patients’ atherogenic profile after cortisol normalization. Importantly, 
BMI z-score showed a positive correlation with GlycA levels (r=0.47), however, we interpret 
this result with caution as obesity itself may contribute to the abnormal GlycA regardless of 
the CD. In our study, the mean BMI z-score improved from 1.88±1.00 pre-surgery to 
1.61±0.78 post-surgery, indicating that obesity was still a consideration despite cortisol 
normalization. Jago et al recently analyzed by NMR spectroscopy GlycA levels in 1664 
adolescents and showed that GlycA was significantly higher in higher BMI groups [19].
While most of the lipid markers (TRLP, LDLP, TC, LDL, apoB) in our study changed in a 
cardiovascular advantageous direction in the post-op samples, this did not hold true for the 
HDL particles and apoA1, which both decreased post-cure of CD. We do not have a 
reasonable explanation for the paradoxical worsening of the HDL markers after 
normalization of the cortisol levels, however this seems to be in accordance with prior 
studies reporting a variable effect of Cushing syndrome on HDL cholesterol; different 
studies have shown both increases and decreases of the HDL and apoA1 levels [20, 21]. Of 
note, the effect of Cushing syndrome on LDL cholesterol and apoB is consistent among 
different series; LDL cholesterol is increased in patients with Cushing syndrome, and it 
often correlates with the severity of the disease [20-22].
Limitations of our study include the relatively small patient population and the retrospective 
design of the study that did not allow us to calculate cardiovascular risk and HOMA-IR 
scores, as we did not routinely get insulin levels and/or waist circumference during CD 
evaluation. Furthermore, the retrospective nature of the study in combination with the rarity 
of CD in pediatrics accounted for the lack of consistency at the post-surgery sampling times 
among our study participants, as most patients were referred to our center by primary 
hospitals across the country. Study limitations also includes lack of a control or comparator 
population for variables that may affect lipid measurements over time, such as pubertal 
change during the study period, race/ethnicity, family history, diet, exercise, body 
composition and concomitant and conditions (including genetic associations).
NMR spectroscopy is an emerging technology in the field of lipidiology; thus its superiority 
in addressing cardiovascular disease parameters as compared to traditional lipid 
concentrations, has not yet been established in the pediatric population. However, recent 
studies have demonstrated that NMR lipid profiles are more strongly associated with 
cardiovascular risk factors in adolescents and young adults compared to conventional lipid 
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profiles [16,17]. Urbina et al [16] compared NMR and traditional lipid profiles in 214 lean, 
228 obese, and 214 T2 diabetic patients (10-24 years old), and found that while LDL 
concentration was similar in the obese and diabetic group, the LDL size measured by NMR, 
was able to differentiate the 3 groups (p≤0.0001). Using general linear models, that included 
patient demographics, risk factors and traditional or NMR lipid parameters and a composite 
vascular function score, the authors demonstrated that NMR lipid profiles were better in 
predicting vascular damage and were more strongly associated to vascular function, as 
compared to traditional lipid profiles. Shah et al [17] compared NMR and traditional lipid 
profiles in 96 obese youth with prediabetes and 118 obese normoglycemic controls and 
report that while conventional lipid profiles were not significantly different between groups, 
patients with prediabetes had higher levels of small LDL-P and HDL-P, as measured by 
NMR.
CD although rare, can serve as a model to study the effect of excess cortisol on 
cardiovascular disease. In our cohort of 33 CD pediatric patients who achieved biochemical 
remission at 1 year post-TSS, there was a significant post-cure reduction in most of the lipid 
variables that were measured, with the exception of the HDL and ApoA1 markers, despite 
the fact that most patients were peri-pubertal, and there is a well-documented tendency of 
lipid profile worsening in puberty. Our hypothesis is that the improvement in the lipid profile 
was due to a combination of lowering the cortisol levels and the BMI. Approaching 
dyslipidemia in patients with CD is challenging; even with normalization of the cortisol 
levels, lipid markers might remain elevated long after remission was achieved, suggesting 
that dyslipidemia in this population should be a life-long concern, with appropriate follow-
up.
In conclusion, NMR lipoprotein profile may serve as a marker of cardiovascular risk in 
pediatric patients with CD. Further studies are needed to see if lipoprotein markers are 
associated with preclinical markers of atherosclerosis in a larger cohort.
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Figure 1. 
Clinically relevant correlations between lipoprotein variables and morning cortisol levels 
before transsphenoidal surgery. a-d: HDL cholesterol, HDL-particle, very small triglyceride 
rich particles, and apolipoprotein A1, showed a significant correlation with morning serum 
cortisol levels (r=−0.50, r=−0.36, r = 0.37, and r= −0.45 respectively).
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Figure 2: 
Pre-transsphenoidal surgeryGlycA showed a positive correlation with BMI z-score (r=0.47)
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Table 1:
NMR lipid variables, clinical and biochemical characteristics at pre- and post- transsphenoidal surgery (TSS) 
in 33 patients with Cushing’s disease in remission
Variable Definitions Reference
Range
(5th – 95th %ile)
Pre-TSS
Value
(mean ± SD)
Post-TSS value
(mean ± SD)
Triglyeride-Rich Particles (nmol/L)
TRLP Total TRLP 42 – 239 120.9 ± 66.8 103.3 ± 47.8
VLTRLP Very Large TRLP 0 – 1.6 0.26 ± 0.23 0.24 ± 0.35
LTRLP Large TRLP 0 – 12.8 4.4 ± 5.1 4.0 ± 5.3
MTRLP Medium TRLP 0.3 – 48.4 8.5 ± 10.2 14.7 ± 11.2
STRLP Small TRLP 7.3 – 124.4 49.5 ± 25.4 53.3 ± 26.2
VSTRLP Very Small TRLP 0 – 142.3 58.2 ± 53.8 31.1 ± 33.4
LDL Particles (nmol/L)
LDLP Total cLDLP 891 – 2150 1751.1 ± 578.5 1479.5 ± 506.2
LLDLP Large LDLP 17 – 748 450.3 ± 279.7 307.4 ± 140.0
MLDLP Medium LDLP 0 – 1377 843.9 ± 662.2 752.7 ± 560.4
SLDLP Small LDLP 13 – 1318 456.9 ± 435.4 419.4 ± 501.0
HDL Particles (μmol/L)
HDLP Total cHDLP 19.2 – 29.3 26.0 ± 4.0 22.4 ± 4.3
LHDLP Large HDLP 0.2 – 6.3 1.9 ± 1.7 2.2 ± 1.6
MHDLP Medium HDLP 3.7 – 12.6 9.4 ± 2.5 7.4 ± 2.0
SHDLP Small HDLP 8.1 – 19.6 14.7 ± 3.3 12.8 ± 3.6
Mean Particle Sizes (nm)
TRLZ TRL Size 33.8 – 60.9 46.9 ± 7.4 45.6 ± 7.9
LDLZ LDL Size 20.1 – 21.7 21.09 ± 0.52 21.04 ± 0.41
HDLZ HDL Size 8.3 – 9.8 8.95 ± 0.34 9.03 ± 0.32
Lipids and Apolipoproteins (mg/dL)
TG Total Triglycerides 43 – 276 107.2 ± 58.6 115.6 ± 61.6
TC Total Cholesterol 140 – 256 222.8 ± 59.7 191.3 ± 50.9
TRLTG TRL Triglycerides 25 – 238 84.9 ± 54.6 96.4 ± 58.2
LDLC LDL Cholesterol 63 – 163 135.1 ± 48.9 112.0 ± 38.4
HDLC HDL Cholesterol 41 – 88 65.0 ± 12.5 57.4 ± 12.9
ApoB Apolipoprotein B 53 – 127 110.6 ± 36.3 94.1 ± 27.9
ApoA-1 Apolipoprotin A-1 116 – 209 156.7 ± 41.6 139.2 ± 43.1
Inflammatory Biomarker (μmol/L)
GlycA GlycA 307 – 524 508.6 ± 110.3 439.6 ± 109.1
Clinical and Biochemical Characteristics
Height Z-score cm n/a −0.69 ± 1.51 −0.75 ± 1.19
BMI Z-score kg/m2 n/a 1.88 ± 1.00 1.61 ± 0.78
SBP Z-score mmHg n/a 1.37 ± 1.12 0.45 ± 1.17
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Variable Definitions Reference
Range
(5th – 95th %ile)
Pre-TSS
Value
(mean ± SD)
Post-TSS value
(mean ± SD)
DBP Z-score mmHg n/a 0.44 ± 1.16 −0.23 ± 0.83
Midnight Serum Cortisol mcg/dl <4.4mcg/dl 17.36 ± 14.51 1.30 ± 0.70
Morning Serum Cortisol mcg/dl 5-25mcg/dl 18.42 ± 13.39 4.77 ± 3.91
24-hour Urinary Free Cortisol mcg/dl 4.0-56mcg/24h 340.10 ± 514.91 6.60 ± 9.03
Fasting plasma glucose mg/dl 70-99mg/dl 111.09 ± 36.56 91.63 ± 13.64
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Table 2:
Demographic data, clinical and biochemical characteristics at diagnosis of 33 patients with CD
Patient characteristics mean ± SD **
Age (years) 13.8 ± 4.0
Gender (n, M/F) 11 / 22
BMI z-score (kg/m2)* 1.88 ± 1.00 (2.27, 1.61 - 2.44)
Height z-score (cm) −0.69 ± 1.51
Tanner stage at diagnosis 3.2 ± 1.5
Systolic BP z-score (mmHg) 1.37 ± 1.12
Diastolic BP z-score (mmHg) 0.44 ± 1.16
Midnight serum cortisol (mcg/dl)* 17.36 ± 14.51 (13.35, 9.55 – 21.35)
Morning serum cortisol (mcg/dl)* 18.42 ± 13.39 (16.35, 12.35 – 19.2)
24-hour Urinary Free Cortisol (mcg/24 hr)* 340.10 ± 514.91 (175.5, 87.6 – 421.9)
Fasting plasma glucose (mg/dl)* 111.09 ± 36.56 (105.0, 91.0 – 114.0)
Time to diagnosis (years) 2.71 ± 1.88
Tumor size (mm)* 6.61 ± 5.04 (6.00, 4.00 - 8.00)
CD severity score* 5.67 ± 1.95 (6.0, 5.0 – 7.0)
Time to post-TSS sampling (months after TSS)* 9.72 ± 10.35 (7.0, 6.0-10.0)
*
not approximately normally distributed variables, for which the median with the interquartile ranges (25th-75th percentiles) are also reported into 
parentheses.
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Table 3:
NMR lipid profile changes from pre- to post- transsphenoidal surgery (TSS) in 33 patients with Cushing’s 
disease in remission
Variable Δ P-value 95% CI
Triglyeride-RichParticles(nmol/L)
TRLP Total TRLP −17.6 0.1147 −39.7 – 4.5
VLTRLP VeryLarge TRLP −0.03 0.1171 −0.18 – 0.12
LTRLP Large TRLP −0.4 0.5226 −2.6 – 1.9
MTRLP Medium TRLP 6.2 0.0305* 1.9 – 10.5
STRLP Small TRLP 3.7 0.4098 −5.4 – 12.9
VSTRLP Very Small TRLP −27.1 0.0162* −44.1 – −10.2
LDL Particles(nmol/L)
LDLP Total cLDLP −271.6 0.0225* −465.4 – −77.7
LLDLP Large LDLP −142.9 0.0140* −235.1 – −50.6
MLDLP Medium LDLP −91.2 0.3985 −308.3 – 125.9
SLDLP Small LDLP −37.5 0.1585 −225.0 – 150.0
HDL Particles(μmol/L)
HDLP Total cHDLP −3.6 0.0004* −5.6 – −1.6
LHDLP Large HDLP 0.3 0.1549 −0.1 – 0.7
MHDLP Medium HDLP −2.0 0.0064* −3.2 – −0.7
SHDLP Small HDLP −1.9 0.0009* •3.2 – −0.8
Mean Particle Sizes (nm)
TRLZ TRL Size −1.3 0.3728 −4.3 – 1.6
LDLZ LDL Size −0.04 0.6269 −0.22 – 0.14
HDLZ HDL Size 0.08 0.1001 −0.02 – 0.18
Lipids and Apolipoproteins(mg/dL)
TG Total Triglycerides 8.4 0.4561 −13.8 – 30.7
TC Total Cholesterol −31.5 0.0069* −53.7 – −9.3
TRLTG TRL Triglycerides 11.5 0.2553 −9.5 – 32.5
LDLC LDL Cholesterol −23.1 0.0068* −39.3 – −6.8
HDLC HDL Cholesterol −7.5 0.0102* −13.2 – −1.9
ApoB Apolipoprotein B −16.5 0.0073* −28.3 – −4.8
ApoA-1 Apolipoprotein A1 −17.5 0.0133* −31.2 – −3.9
InflammatoryBiomarker(μmol/L)
GlycA Glycosylated acute phase proteins −69.0 0.0050* −115.6 – −22.4
*
statistically significant at p<0.05, corrected for multiple comparisons as applicable
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Table 4:
Statistically significant and potentially important correlations of lipid variables with Cushing’sdisease (CD) 
severity score variables
Lipid Profile Variable CD Severity Score
Variable
Correlation
Coefficient (r) *
95% CI P-value
Medium TriglycerideRichparticle (MTRLP) Total severity score −0.40 −0.65 – −0.07 0.020
24h Urinary free cortisol −0.40 −0.66 – −0.07 0.020
Midnightserum cortisol −0.36 −0.62 – −0.02 0.041
VerysmallTriglycerideRichparticle (VSTRLP) Morningserum cortisol 0.37 0.03 – 0.63 0.034
Large LDL-particle (LLDLP) Age at surgery −0.39 −0.65 – −0.06 0.023
Total HDL-particle (HDLP) Morningserum cortisol −0.36 −0.63 – −0.02 0.038
Medium HDL-particle (MHDLP) BMI z-score 0.46 0.13 – 0.70 0.008
HDL mean particlesize (HDLZ) Age at surgery −0.40 −0.66 – −0.07 0.020
HDL colesterol (HDLC) Morningserum cortisol −0.50 −0.72 – −0.19 0.003
Apolipoprotin A-1(ApoA1) Morningserum cortisol −0.45 −0.69 – −0.12 0.009
GlycA BMI z-score 0.47 0.14 – 0.71 0.007
*Correlation coefficients are either Pearson’s or Spearman’s, as applicable; 95% Confidence Intervals (CIs) and p-values are based on Fisher’s z 
transformation.
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